



- (51) **International Patent Classification:**
C12N 15/867 (2006.01) C07K 14/145 (2006.01)
- (21) **International Application Number:**
PCT/EP2024/068518
- (22) **International Filing Date:**
01 July 2024 (01.07.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
23182836.9 30 June 2023 (30.06.2023) EP
- (71) **Applicant:** ESOBIOTEC [BE/BE]; Rue André Dumont 5, 1435 Mont-Saint-Guibert (BE).
- (72) **Inventors:** PARONE, Philippe; EsoBiotec, Rue André Dumont 5, 1435 Mont-Saint-Guibert (BE). LATERE, Jean-Pierre; EsoBiotec, Rue André Dumont 5, 1435 Mont-Saint-Guibert (BE). DOIX, Bastien; EsoBiotec, Rue André Dumont 5, 1435 Mont-Saint-Guibert (BE). GALVIS, Laura; EsoBiotec, Rue André Dumont 5, 1435 Mont-Saint-

Guibert (BE). WEBSTER, Brian; EsoBiotec, Rue André Dumont 5, 1435 Mont-Saint-Guibert (BE). ABI HABIB, Joanna; EsoBiotec, Rue André Dumont 5, 1435 Mont-Saint-Guibert (BE). DRAPPIER, Melissa; EsoBiotec, Rue André Dumont 5, 1435 Mont-Saint-Guibert (BE). FIÉVET, Alexia; EsoBiotec, Rue André Dumont 5, 1435 Mont-Saint-Guibert (BE). WEERENS, Laura; EsoBiotec, Rue André Dumont 5, 1435 Mont-Saint-Guibert (BE). PECENKO, Sylvia; EsoBiotec, Rue André Dumont 5, 1435 Mont-Saint-Guibert (BE).

(74) **Agent:** EYRE, David Edward; Schlich, 9 St Catherine's Road, Littlehampton Sussex BN17 5HS (GB).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) **Title:** VIRAL VECTOR AND PRODUCER CELL




Fig. 1

(57) **Abstract:** There is provided a viral vector having a lipid bilayer envelope comprising an antibody binding domain displayed on the exterior of the envelope that is cell-type specific; a viral envelope protein displayed on the exterior of the envelope that is able to facilitate infection of the same cell type; and a nucleic acid molecule comprising a promoter expressible in the same cell type. Further provided are methods of making the viral vector and methods of using the viral vector to modify cells and treat diseases / conditions.

[Continued on next page]

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*